Here are 1-3 brief analogies to describe Immunome (IMNM):

• Regeneron for early-stage antibody drugs in cancer and COVID-19.
• A nascent Genentech, but focused on antibody therapies for oncology and viral infections.

• IMM-ONC-01: An oncology antibody therapeutic program targeting IL-38 to promote immune system evasion.
• IMM-BCP-01: An antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.

Immunome, Inc. (symbol: IMNM) is a biopharmaceutical company primarily focused on the discovery and development of antibody therapeutics for oncology and infectious disease. Based on the provided background information, the company is engaged in advancing its lead oncology program (IMM-ONC-01) and an antibody cocktail product candidate for infectious disease (IMM-BCP-01).

As a company primarily involved in the research and development phase with pipeline "product candidates," Immunome does not currently have major direct customers in the traditional sense of selling commercialized products to individuals or other companies.

Typically, a biopharmaceutical company at this stage aims to develop its drug candidates through clinical trials. If successful, these candidates may eventually be:

• Licensed to larger pharmaceutical companies for further development, manufacturing, and commercialization. In this scenario, the licensing partners would be considered their "customers" in a business-to-business relationship.
• Commercialized directly by Immunome, which would involve selling to healthcare providers (e.g., hospitals, clinics, pharmacies) or government health organizations.

However, based solely on the description of Immunome's current activities as "discovering and developing" "product candidates," there are no identifiable major customers for commercial products at this time.

Clay Siegall, Ph.D. President & Chief Executive Officer

Dr. Siegall was appointed President & Chief Executive Officer of Immunome in October 2023. He previously served as CEO of Morphimmune, a privately held biotechnology company that successfully merged with Immunome under his leadership. Dr. Siegall is also a co-founder and former CEO of Seagen, Inc., which was acquired by Pfizer for $43 billion. He has over 25 years of experience in the biopharmaceutical industry.

Max Rosett Chief Financial Officer

Mr. Rosett joined Immunome in October 2023, following the company's merger with Morphimmune, where he previously served as Acting Chief Operating Officer. Before Morphimmune, he was a Principal at Research Bridge Partners, a life science investment firm. Mr. Rosett also worked as a software engineer at Google and began his career at the Boston Consulting Group, advising clients in the pharmaceutical industry.

Jack Higgins, Ph.D. Chief Scientific Officer

Dr. Higgins is the Chief Scientific Officer at Immunome.

Kinney Horn Chief Business Officer

Mr. Horn serves as the Chief Business Officer, bringing over two decades of experience in life science finance and business development to Immunome.

Bob Lechleider, M.D. Chief Medical Officer

Dr. Lechleider holds the position of Chief Medical Officer at Immunome.

Immunome, Inc. (IMNM) faces several key risks inherent to its operations as a biopharmaceutical company focused on discovering and developing antibody therapeutics. These risks are primarily centered around the challenging and costly nature of drug development, market competition, and financial sustainability.

1. Clinical Trial and Regulatory Approval Risk: As a biopharmaceutical company, Immunome's success is heavily dependent on the successful outcome of its clinical trials and the ability to secure regulatory approvals for its product candidates. The drug development process is lengthy, expensive, and uncertain, with a high rate of failure at various stages. Even with positive Phase 3 results for a lead candidate like varegacestat, there is no guarantee of New Drug Application (NDA) submission leading to regulatory approval or successful commercialization.
2. Product Pipeline Concentration and Commercialization Challenges: Immunome's future revenue and profitability are largely tied to the success of a limited number of product candidates. While the company has demonstrated progress with its varegacestat program and has other candidates like IM-1021 in earlier phases and planned IND submissions, the commercial success of these assets is not assured. The market for desmoid tumors, for which varegacestat is being developed, is small, and the company faces intense competition from existing treatments and other companies with greater financial resources and established market presence in both oncology and infectious disease fields.
3. Financial Sustainability and Need for Additional Funding: Immunome is a development-stage company with minimal current revenue and a history of significant operating losses. Advancing product candidates through clinical development to potential commercialization requires substantial capital. Although the company recently conducted a public offering to extend its cash runway, there remains a risk of needing to raise additional capital in the future, which could lead to further shareholder dilution or impact the company's ability to fund its research and development activities.

The rapidly evolving landscape of COVID-19 treatment and prevention, including the emergence of highly effective oral antivirals, widespread vaccination, and the continuous evolution of SARS-CoV-2 variants, poses a significant threat to the market viability and relevance of Immunome's antibody cocktail product candidate, IMM-BCP-01, for SARS-CoV-2 infections and COVID-19.

Immunome (NASDAQ: IMNM) focuses on developing antibody therapeutics for oncology and infectious diseases.

IMM-ONC-01 (Oncology)

Immunome's lead oncology program, IMM-ONC-01, targets IL-38, a tumor-derived immune checkpoint. While a specific addressable market size for IL-38 inhibitors is not readily available, IMM-ONC-01 falls under the broader categories of Immuno-Oncology (IO) and Immune Checkpoint Inhibitors.

• The global immuno-oncology (IO) market was estimated at approximately USD 43.73 billion in 2023 and is projected to reach around USD 284.29 billion by 2033. Another estimate places the global immuno-oncology (IO) market size at USD 54.35 billion in 2025, projected to hit approximately USD 435.70 billion by 2035.
• The global immune checkpoint inhibitors market was valued at an estimated USD 48.42 billion in 2023 and is projected to reach USD 154.25 billion by 2030. This market was valued at USD 66.2 billion in 2025 and is expected to grow to USD 303.9 billion in 2035.
• North America has consistently dominated these markets, holding the largest share in 2023, 2024, and 2025.

IMM-BCP-01 (SARS-CoV-2/COVID-19)

IMM-BCP-01 was an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. However, the development of IMM-BCP-01 has been discontinued.

Immunome (IMNM) is poised for potential future revenue growth over the next 2-3 years, driven primarily by the advancement and potential commercialization of its oncology pipeline. The company's focus is on developing first-in-class and best-in-class targeted cancer therapies.

1. Regulatory Approval and Commercialization of Varegacestat (formerly AL102) for Desmoid Tumors: Immunome's lead program, varegacestat, a once-daily oral gamma secretase inhibitor, achieved positive topline results from the pivotal Phase 3 RINGSIDE trial in December 2025. This trial demonstrated an 84% reduction in the risk of disease progression or death and a 56% objective response rate in patients with desmoid tumors. An New Drug Application (NDA) submission for varegacestat is planned for the second quarter of 2026. Successful regulatory approval and subsequent commercial launch would be a significant new revenue stream, with estimated conservative peak global sales potentially reaching $280 million.
2. Advancement and Potential Commercialization of IM-1021 (ROR1 ADC): Immunome is progressing IM-1021, a ROR1-targeted Antibody-Drug Conjugate (ADC), through its Phase 1 clinical trial for solid tumors and B-cell lymphomas. The company received IND clearance for IM-1021 in the fourth quarter of 2024, and initial data from the ongoing Phase 1 study is anticipated in 2026. IM-1021 incorporates Immunome's proprietary TOP1 inhibitor, HC74, designed to overcome common ADC resistance mechanisms. Positive clinical outcomes and progression to later-stage development or potential partnerships could drive future revenue.
3. Progression of IM-3050 (FAP-targeted Radiotherapy) into Clinical Development: IM-3050, a Fibroblast Activating Protein (FAP)-targeted lutetium-177 radioligand therapy, received IND clearance in April 2025, with the initiation of a Phase 1 clinical trial expected in early 2026 or the second half of 2025. Successful advancement of this novel therapeutic modality could create future revenue opportunities through development milestones, licensing agreements, or eventual commercialization.
4. Expansion and Advancement of the Broader Antibody-Drug Conjugate (ADC) Pipeline: Beyond IM-1021, Immunome is actively building a robust pipeline of early-stage ADCs targeting various solid tumors. The company has three preclinical solid-tumor ADCs (IM-1617, IM-1340, IM-1335) with IND-enabling work underway and anticipated IND submissions in 2026. The strategic focus on developing differentiated ADCs with novel targets presents multiple opportunities for future collaboration revenue, milestone payments, and potential product sales as these programs advance.

Share Issuance

• A new shelf registration for up to approximately $156 million in common stock was reported on March 11, 2026.
• An underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending the projected cash runway into 2028.
• In January 2025, Immunome announced plans for an underwritten public offering to issue and sell $125.0 million of shares of its common stock.

Inbound Investments

• In October 2023, Immunome completed a merger with Morphimmune, which included a $125 million private placement investment from leading institutional investors such as Enavate Sciences, EcoR1 Capital, Redmile Group, Janus Henderson Investors, Avidity Partners, and Woodline Partners LP.
• Redmile Group increased its position in Immunome during the fourth quarter of 2025 by 695,000 shares, an estimated $12.20 million trade, bringing their stake to 9.05% of their 13F assets under management as of December 31, 2025.

Outbound Investments

• In January 2024, Immunome licensed ZPC-21 (now IM-1021), a ROR1 antibody-drug conjugate, and ADC platform technology from Zentalis Pharmaceuticals, with an upfront payment of $35 million in cash and Immunome stock, and potential milestones of up to $275 million plus royalties.
• On March 26, 2024, Immunome completed the acquisition of varegacestat (formerly AL102) and AL101 from Ayala Pharmaceuticals for an upfront payment of $20 million in cash and $30 million in Immunome common stock, along with an additional $37.5 million in milestones.
• On December 26, 2023, Immunome announced the acquisition of antibody-related assets and materials from Atreca for an upfront payment of $5.5 million, with potential for an additional $7 million in clinical development milestones.

Capital Expenditures

• Research and development expenses for the year ended December 31, 2025, were $177.3 million.
• In-process research and development expenses for the year ended December 31, 2025, were $10.0 million, specifically tied to a development milestone for the Phase 3 RINGSIDE trial of varegacestat.
• Funds from recent offerings are intended to support the potential commercial launch of varegacestat and the further development of their pipeline, with the company expecting its current cash to fund operations into 2028.